Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001913252 | SCV002176018 | uncertain significance | not provided | 2022-01-14 | criteria provided, single submitter | clinical testing | In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may create or strengthen a splice site. Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt SLC12A2 protein function. This variant has not been reported in the literature in individuals affected with SLC12A2-related conditions. This variant is present in population databases (rs548545596, gnomAD 0.01%). This sequence change replaces leucine, which is neutral and non-polar, with valine, which is neutral and non-polar, at codon 765 of the SLC12A2 protein (p.Leu765Val). |
Fulgent Genetics, |
RCV002478318 | SCV002784576 | uncertain significance | Kilquist syndrome; Hearing loss, autosomal dominant 78; Delpire-McNeill syndrome | 2021-09-30 | criteria provided, single submitter | clinical testing |